However, as always there are externalities. So far, BRCA gene screening was only done for women with a family history of breast cancer. One fears that now eve

However, as always there are externalities. So far, BRCA gene screening was only done for women with a family history of breast cancer. One fears that now everyone with a 23andme positive test result will consult their physician, and if their test yields too many false positives this will be a plain waste of money. I don't want to pay for someone else's unvalidated test. The strategy of 23andme is to collect genomic data and correlate it with phenotypic data to get a handle on variations. They will sell the data, either to pharmcos or themselves; if they do it themselves they will need to do trialing to ensure that their test does measure what they say it measures. This stunt serves to hollow out the FDA and get an end-run around clinical trials.